GLP-1 drugs and PCOS weight loss: what the evidence actually shows

What did @catreaamcknight actually say?

Almost nothing medically substantive, and that's worth noting plainly. The creator's transcript is entirely motivational filler: "Girl, it's your season," "get out your head," "it is your time to shine." There are no clinical claims, no dosing advice, no promises about what GLP-1 medications will do to your body. The actual health content here is zero words long.

What the video does do is pair that emotional encouragement with a paid partnership disclosure (#mochipartner) and a $40 discount link to Mochi Health, a telehealth platform that prescribes GLP-1 receptor agonists. The hashtags #pcos, #glp1, and #bodytransformation signal the intended audience clearly, even if the spoken words don't. Context is doing the heavy lifting that the transcript isn't.

Does the science back this up?

There's nothing specific to fact-check in the transcript itself, but the implicit framing, that GLP-1 medications are an accessible, season-changing solution for people with PCOS, does have a scientific basis worth examining honestly.

GLP-1 receptor agonists like semaglutide and tirzepatide have shown real benefit in people with polycystic ovary syndrome. A 2023 randomized controlled trial by Jensterle et al. published in Diabetes, Obesity and Metabolism found semaglutide produced significant weight reduction and improved metabolic markers in women with PCOS compared to placebo. Tirzepatide data from the SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) showed up to 22.5% mean body weight reduction in adults with obesity, a population that overlaps substantially with PCOS patients. These are not small effects. The science behind the category being promoted is reasonably solid. The video just doesn't mention any of it.

What did they get wrong (or right)?

The creator didn't get anything medically wrong because they didn't say anything medical. That's genuinely the cleanest outcome in GLP-1 influencer content, where the common failure mode is overclaiming. No one here is saying semaglutide will cure your PCOS, fix your hormones permanently, or replace lifestyle changes. Credit where it's due.

What's missing is disclosure of risk. A viewer with PCOS watching a #mochipartner video and clicking a discount link deserves to know that GLP-1 medications carry real side effects: nausea, vomiting, and gastrointestinal distress affect a significant portion of users. The FDA has also flagged thyroid C-cell tumor risks in rodent studies for semaglutide, and the drug carries a black box warning for patients with a personal or family history of medullary thyroid carcinoma. Telehealth prescribing platforms like Mochi operate legally and can provide legitimate care, but a hype reel with a promo code is not informed consent.

What should you actually know?

If you have PCOS and you're considering a GLP-1 medication through a telehealth platform, the biology is not working against you. Insulin resistance is a core driver of PCOS for many patients, and GLP-1 agonists address that mechanism directly. A 2022 meta-analysis by Lim et al. in Frontiers in Endocrinology found GLP-1 receptor agonists significantly reduced BMI, fasting insulin, and testosterone levels in women with PCOS across multiple trials.

But "your season" framing glosses over real considerations. Not everyone qualifies. These medications interact with other drugs, are contraindicated in certain conditions, and require ongoing monitoring. Compounded versions of semaglutide and tirzepatide, which some telehealth platforms have offered, are not equivalent to FDA-approved branded formulations and carry their own regulatory and quality concerns. The FDA has explicitly warned consumers about this.

• GLP-1 agonists have legitimate, study-backed utility in PCOS-related metabolic dysfunction.
• A discount code is not a clinical evaluation.
• Ask any prescriber about thyroid history, pancreatitis history, and current medications before starting.
• Telehealth can be legitimate care. It can also be a funnel. Those are not mutually exclusive.

Bottom line

This video is a paid ad dressed in empowerment language. That's not inherently dishonest, the #mochipartner tag is there, and the motivational tone doesn't make false claims. But viewers arriving from a PCOS hashtag search deserve more than vibes and a promo code. The science supporting GLP-1 use in PCOS is real. This video just doesn't show any of it.